Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Margin of Safety % (DCF FCF Based): N/A (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08329 Shenzhen Neptunus Interlong Bio-Technique Co Ltd HKSE:08329
48 GF Score
Price HK$0.10
GF Value HK$0.14
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Shenzhen Neptunus Interlong Bio-Technique Co Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Shenzhen Neptunus Interlong Bio-Technique Co's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

HKSE:08329 vs ZTS: Margin of Safety % (DCF FCF Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Neptunus Interlong Bio-Technique Co's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shenzhen Neptunus Interlong Bio-Technique Co Margin of Safety % (DCF FCF Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Neptunus Interlong Bio-Technique Co's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Shenzhen Neptunus Interlong Bio-Technique Co's Margin of Safety % (DCF FCF Based) falls into.


HKSE:08329
48GF Score
Shenzhen Neptunus Interlong Bio-Technique Co Ltd HKSE:08329
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Overvalued in 2026?

Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co stock appears to be undervalued. The current stock price of HK$0.10 is trading 29.3% below its estimated GF Value™ of HK$0.14. GuruFocus considers Shenzhen Neptunus Interlong Bio-Technique Co to be Modestly Undervalued.

Key valuation signals for HKSE:08329:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: HK$0.14 vs. price of HK$0.10 (29.3% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the HKSE:08329 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shenzhen Neptunus Interlong Bio-Technique Co Business Description

Address 979 King’s Road, 43rd Floor, One Taikoo Place, Quarry Bay, Hong Kong, HKG
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sale of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines and medical devices; and the Sales and distribution of medicines, healthcare products, and medical devices.. The majority of revenue is generated from the Manufacturing and selling of medicines and medical devices segment.
48GF Score

Get the complete analysis for HKSE:08329

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.10
Price
HK$0.14
GF Value